Neurodegenerative Disease Market Size & Demand By 2030

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Neurodegenerative Disease Market Size Analysis

Global Neurodegenerative Disease Market Introduction
By Indication Type
1. Introduction
  1. Indication Type By Value
2. Parkinson's Disease
  1. By Value
3. Alzheimer's Disease
  1. By Value
4. Multiple Sclerosis
  1. By Value
5. Huntington Disease
  1. By Value
6. Amyotrophic Lateral Sclerosis
  1. By Value
7. Spinal Muscular Atrophy (SMA)
  1. By Value
8. Other Indication Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. N-methyl-D-aspartate Receptor antagonists
  1. By Value
3. Cholinesterase Inhibitors
  1. By Value
4. Dopamine Agonists
  1. By Value
5. Immunomodulatory Drugs
  1. By Value
6. Acetylcholinesterase (AChE) Inhibitors
  1. By Value
7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
  1. By Value
8. Catechol-O-Methyltransferase (COMT) Inhibitor
  1. By Value
9. SSRIs
  1. By Value
10. Other Drug Types
  1. By Value

North America Market Analysis

Introduction
By Indication Type
1. Introduction
  1. Indication Type By Value
2. Parkinson's Disease
  1. By Value
3. Alzheimer's Disease
  1. By Value
4. Multiple Sclerosis
  1. By Value
5. Huntington Disease
  1. By Value
6. Amyotrophic Lateral Sclerosis
  1. By Value
7. Spinal Muscular Atrophy (SMA)
  1. By Value
8. Other Indication Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. N-methyl-D-aspartate Receptor antagonists
  1. By Value
3. Cholinesterase Inhibitors
  1. By Value
4. Dopamine Agonists
  1. By Value
5. Immunomodulatory Drugs
  1. By Value
6. Acetylcholinesterase (AChE) Inhibitors
  1. By Value
7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
  1. By Value
8. Catechol-O-Methyltransferase (COMT) Inhibitor
  1. By Value
9. SSRIs
  1. By Value
10. Other Drug Types
  1. By Value
U.S.
1. By Indication Type
  1. Introduction
    1. Indication Type By Value
  2. Parkinson's Disease
    1. By Value
  3. Alzheimer's Disease
    1. By Value
  4. Multiple Sclerosis
    1. By Value
  5. Huntington Disease
    1. By Value
  6. Amyotrophic Lateral Sclerosis
    1. By Value
  7. Spinal Muscular Atrophy (SMA)
    1. By Value
  8. Other Indication Types
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. N-methyl-D-aspartate Receptor antagonists
    1. By Value
  3. Cholinesterase Inhibitors
    1. By Value
  4. Dopamine Agonists
    1. By Value
  5. Immunomodulatory Drugs
    1. By Value
  6. Acetylcholinesterase (AChE) Inhibitors
    1. By Value
  7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
    1. By Value
  8. Catechol-O-Methyltransferase (COMT) Inhibitor
    1. By Value
  9. SSRIs
    1. By Value
  10. Other Drug Types
    1. By Value
Canada

Europe Market Analysis

Introduction
By Indication Type
1. Introduction
  1. Indication Type By Value
2. Parkinson's Disease
  1. By Value
3. Alzheimer's Disease
  1. By Value
4. Multiple Sclerosis
  1. By Value
5. Huntington Disease
  1. By Value
6. Amyotrophic Lateral Sclerosis
  1. By Value
7. Spinal Muscular Atrophy (SMA)
  1. By Value
8. Other Indication Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. N-methyl-D-aspartate Receptor antagonists
  1. By Value
3. Cholinesterase Inhibitors
  1. By Value
4. Dopamine Agonists
  1. By Value
5. Immunomodulatory Drugs
  1. By Value
6. Acetylcholinesterase (AChE) Inhibitors
  1. By Value
7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
  1. By Value
8. Catechol-O-Methyltransferase (COMT) Inhibitor
  1. By Value
9. SSRIs
  1. By Value
10. Other Drug Types
  1. By Value
U.K.
1. By Indication Type
  1. Introduction
    1. Indication Type By Value
  2. Parkinson's Disease
    1. By Value
  3. Alzheimer's Disease
    1. By Value
  4. Multiple Sclerosis
    1. By Value
  5. Huntington Disease
    1. By Value
  6. Amyotrophic Lateral Sclerosis
    1. By Value
  7. Spinal Muscular Atrophy (SMA)
    1. By Value
  8. Other Indication Types
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. N-methyl-D-aspartate Receptor antagonists
    1. By Value
  3. Cholinesterase Inhibitors
    1. By Value
  4. Dopamine Agonists
    1. By Value
  5. Immunomodulatory Drugs
    1. By Value
  6. Acetylcholinesterase (AChE) Inhibitors
    1. By Value
  7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
    1. By Value
  8. Catechol-O-Methyltransferase (COMT) Inhibitor
    1. By Value
  9. SSRIs
    1. By Value
  10. Other Drug Types
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Indication Type
1. Introduction
  1. Indication Type By Value
2. Parkinson's Disease
  1. By Value
3. Alzheimer's Disease
  1. By Value
4. Multiple Sclerosis
  1. By Value
5. Huntington Disease
  1. By Value
6. Amyotrophic Lateral Sclerosis
  1. By Value
7. Spinal Muscular Atrophy (SMA)
  1. By Value
8. Other Indication Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. N-methyl-D-aspartate Receptor antagonists
  1. By Value
3. Cholinesterase Inhibitors
  1. By Value
4. Dopamine Agonists
  1. By Value
5. Immunomodulatory Drugs
  1. By Value
6. Acetylcholinesterase (AChE) Inhibitors
  1. By Value
7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
  1. By Value
8. Catechol-O-Methyltransferase (COMT) Inhibitor
  1. By Value
9. SSRIs
  1. By Value
10. Other Drug Types
  1. By Value
China
1. By Indication Type
  1. Introduction
    1. Indication Type By Value
  2. Parkinson's Disease
    1. By Value
  3. Alzheimer's Disease
    1. By Value
  4. Multiple Sclerosis
    1. By Value
  5. Huntington Disease
    1. By Value
  6. Amyotrophic Lateral Sclerosis
    1. By Value
  7. Spinal Muscular Atrophy (SMA)
    1. By Value
  8. Other Indication Types
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. N-methyl-D-aspartate Receptor antagonists
    1. By Value
  3. Cholinesterase Inhibitors
    1. By Value
  4. Dopamine Agonists
    1. By Value
  5. Immunomodulatory Drugs
    1. By Value
  6. Acetylcholinesterase (AChE) Inhibitors
    1. By Value
  7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
    1. By Value
  8. Catechol-O-Methyltransferase (COMT) Inhibitor
    1. By Value
  9. SSRIs
    1. By Value
  10. Other Drug Types
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Indication Type
1. Introduction
  1. Indication Type By Value
2. Parkinson's Disease
  1. By Value
3. Alzheimer's Disease
  1. By Value
4. Multiple Sclerosis
  1. By Value
5. Huntington Disease
  1. By Value
6. Amyotrophic Lateral Sclerosis
  1. By Value
7. Spinal Muscular Atrophy (SMA)
  1. By Value
8. Other Indication Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. N-methyl-D-aspartate Receptor antagonists
  1. By Value
3. Cholinesterase Inhibitors
  1. By Value
4. Dopamine Agonists
  1. By Value
5. Immunomodulatory Drugs
  1. By Value
6. Acetylcholinesterase (AChE) Inhibitors
  1. By Value
7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
  1. By Value
8. Catechol-O-Methyltransferase (COMT) Inhibitor
  1. By Value
9. SSRIs
  1. By Value
10. Other Drug Types
  1. By Value
UAE
1. By Indication Type
  1. Introduction
    1. Indication Type By Value
  2. Parkinson's Disease
    1. By Value
  3. Alzheimer's Disease
    1. By Value
  4. Multiple Sclerosis
    1. By Value
  5. Huntington Disease
    1. By Value
  6. Amyotrophic Lateral Sclerosis
    1. By Value
  7. Spinal Muscular Atrophy (SMA)
    1. By Value
  8. Other Indication Types
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. N-methyl-D-aspartate Receptor antagonists
    1. By Value
  3. Cholinesterase Inhibitors
    1. By Value
  4. Dopamine Agonists
    1. By Value
  5. Immunomodulatory Drugs
    1. By Value
  6. Acetylcholinesterase (AChE) Inhibitors
    1. By Value
  7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
    1. By Value
  8. Catechol-O-Methyltransferase (COMT) Inhibitor
    1. By Value
  9. SSRIs
    1. By Value
  10. Other Drug Types
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Indication Type
1. Introduction
  1. Indication Type By Value
2. Parkinson's Disease
  1. By Value
3. Alzheimer's Disease
  1. By Value
4. Multiple Sclerosis
  1. By Value
5. Huntington Disease
  1. By Value
6. Amyotrophic Lateral Sclerosis
  1. By Value
7. Spinal Muscular Atrophy (SMA)
  1. By Value
8. Other Indication Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. N-methyl-D-aspartate Receptor antagonists
  1. By Value
3. Cholinesterase Inhibitors
  1. By Value
4. Dopamine Agonists
  1. By Value
5. Immunomodulatory Drugs
  1. By Value
6. Acetylcholinesterase (AChE) Inhibitors
  1. By Value
7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
  1. By Value
8. Catechol-O-Methyltransferase (COMT) Inhibitor
  1. By Value
9. SSRIs
  1. By Value
10. Other Drug Types
  1. By Value
Brazil
1. By Indication Type
  1. Introduction
    1. Indication Type By Value
  2. Parkinson's Disease
    1. By Value
  3. Alzheimer's Disease
    1. By Value
  4. Multiple Sclerosis
    1. By Value
  5. Huntington Disease
    1. By Value
  6. Amyotrophic Lateral Sclerosis
    1. By Value
  7. Spinal Muscular Atrophy (SMA)
    1. By Value
  8. Other Indication Types
    1. By Value
2. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. N-methyl-D-aspartate Receptor antagonists
    1. By Value
  3. Cholinesterase Inhibitors
    1. By Value
  4. Dopamine Agonists
    1. By Value
  5. Immunomodulatory Drugs
    1. By Value
  6. Acetylcholinesterase (AChE) Inhibitors
    1. By Value
  7. Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor
    1. By Value
  8. Catechol-O-Methyltransferase (COMT) Inhibitor
    1. By Value
  9. SSRIs
    1. By Value
  10. Other Drug Types
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Neurodegenerative Disease Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Abbvie Inc
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Amneal Pharmaceuticals Inc.
Boehringer Ingelheim International GmbHF
Hoffmann-La Roche
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceuticals Ltd
UCB SA
Biogen Inc

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment